Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017
by from Morbidity and Mortality Weekly Report (MMWR) on (#3Y8DS)
Delamanid, a nitro-imidazole, is a new tuberculosis (TB) drug developed to address some of the adverse reactions and related adherence difficulties associated with currently available mediations for treating drug-resistant TB. A patient with extensively drug-resistant TB was successfully treated in 2017.